How immuno-oncology M&A performed in the pharmaceutical industry in Q3 2023
In value terms, immuno-oncology-related deal activity decreased by 92% in Q3 2023 compared with the previous quarter’s total of $6.9bn and fell by 94% as compared to Q3 2022. Related deal volume decreased by 77% in Q3 2023 versus the previous quarter and was 60% lower than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Centerview Partners; Guggenheim Partners; HC Wainwright with 3, 2, 2 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Cooley; Goodwin Procter; Gibson, Dunn & Crutcher with 5, 5, 4 deals respectively.
For further understanding of GlobalData’s Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
Source link
#immunooncology #performed #pharmaceutical #industry
